Supporting our study, vitamin D administration at a dosage of 50,000 IU/week for 8 weeks in VD-deficient subjects with PCOS significantly decreased the bioavailability of TGF-β1 (Irani et al., 2015). Here, TGFB1 is linked to polycystic ovary syndrome.